Bacillus subtilis/Enterococcus faecium/mosapride

Drug Profile

Bacillus subtilis/Enterococcus faecium/mosapride

Alternative Names: HCP 0613; Medilac/mosapride; Medirac/mosapride; Mosapride/Bacillus subtilis/Enterococcus faecium; Mosapride/Bacillus subtilis/Streptococcus faecium; Mosapride/Enterococcus faecium/Bacillus subtilis; Mosapride/Medilac; Mosapride/Medirac; Mosapride/probiotics; Probiotics/mosapride

Latest Information Update: 17 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Bacteria; Benzamides; Gastrokinetics; Morpholines; Probiotics; Small molecules
  • Mechanism of Action Bacteria replacements; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 31 Jan 2012 Bacillus subtilis/Enterococcus faecium/mosapride is available for licensing
  • 01 May 2011 Phase-II clinical trials in Irritable bowel syndrome in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top